and TGC were purchased from Difco Laboratories, Detroit, MI. Mineral oil was obtained from Aldrich Chemical Co., Milwaukee, WI.
Cell Preparation. Peritoneal exudate cells (PEC) were obtained from the peritoneal cavity of mice treated with TGC or PP (1 ml/mouse of a 10% solution, day -4), pyran (25 mg/kg of body weight, day -8) or C. parvum (2. 1 mg/mouse, day -8). To obtain purified macrophages, PEC were incubated in petri dishes (100 × 15 mm) for 1-3 h at 37°C, and adherent cells (macrophages) were obtained from the plates by gently scraping with a rubber policeman after removing nonadherent cells. For the preparation of neutrophils, mice were treated intraperitoneally with TGC (-18 h) and peritoneal exudate cells were harvested. Blood monocytes were purified from peripheral blood by adherence.
Cell Fusion. Immune spleen cells from LOU/CN rats primed with two injections of pyranactivated PEC from C3H/HeN or BALB/c mice were fused with the P3 × 63AgSU1 (P3U1) mouse myeloma cells as described previously (14, 15) . Screening for a hybridoma secreting a monoclonal antibody specific for activated macrophages was by a 125I-labeled protein, a binding assay on pyran-activated macrophages, or TGC-elicited macrophages. Hybridoma with appropriate characteristics was cloned twice by the limiting dilution method and then used for the present study.
Binding Assay. The cells (2-5 × 105 cells in 50 /~1 of phosphate-buffered saline [PBS] containing 2% bovine serum albumin [BSA] and I0 mM NaNs) were first incubated for 2-3 h at 4°C with 50 #1 of hybridoma supernatant in microtest plates, washed in PBS containing 2% BSA and 10 mM NaNz, followed by incubation for 4-6 h with 12SI-labeled protein A (30,000-100,000 cpm/well) at 4°C. After incubation, the cells were washed twice, and the radioactivity of l~6I-labeled protein A bound to cell surfaces was counted by a gamma counter. Fluorescence Study. Aliquots of 1-3 × 106 cells to be stained were pelleted by centrifugation and incubated with 10-20 pl of biotinylated AcM.1 antibody (1 mg/ml) for 30 rain on ice. After washing with 10 ml of cold PBS containing 0.5% BSA and 10 mM NaNs, the cells were resuspended in 10-20/~1 of fluorescein isothiocyanate (FITC)-conjugated avidin (FITC-avidin, 1 mg/ml, E. Y. Laboratories, Inc., San Mateo, CA), and the mixture was further incubated for 20 min on ice. After washings, the cells were examined with a Zeiss fluorescence microscope (Carl Zeiss, Inc., New York). Cytofluorometry was performed with the EPICS V cell sorter (Coulter Electronics Inc., Hialeah, FL), using appropriate scatter windows to screen out cellular debris, dead cells, and cell aggregates (laser power, 800 mW; fluorescence gain 20; and photomultiplier, 750-800 V). Macrophage-mediated Cytotoxicity. Macrophage-mediated cytotoxicity was assessed as described previously (17) . Target cells were labeled with 100-200 #Ci of sodium Sachromate (New England Nuclear, Boston, MA) for 60 min at 37°C, washed three times, and then added to effector cells at 5 × 10 ~ cells/well. After 18 h of incubation, the plates were centrifuged for 10 rain at 350 g, 0.1 ml of supernatant was harvested, and the radioactivity was counted in a gamma counter. The percent of specific cytotoxicity was calculated as: ([cpm in experimental group -cpm with thymocyte control]/[total cpm incorporated into target cells -cpm with thymocyte control]) × 100. The baseline control release of the target cells cultured with thymocytes for 18 h varied between 20.3 and 31.6% of the total radioactivity incorporated.
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Results and Discussion
From approximately 600 hybrids obtained from four separate experiments, in which immune spleen cells from LOU/CN rats treated with multiple injections of pyran-activated PEC of C3H/HeN or BALB/c mice were fused with the P3U1 mouse myeloma cells, we obtained only one stable clone secreting a monoclonal antibody, termed AcM. 1, specific for pyran-activated macrophages but not TGC-elicited macrophages (mff), cloned twice and used for the present study. The isotype of the antibody was IgG2¢ and it had the capacity to fix C. The specificity of the AcM. 1 monoclonal antibody was determined by fluorescence microscopy, ~25I-labeled protein A-binding assay, and C-dependent cytotoxicity. As shown in Table I , the AcM.1 monoclonal antibody reacted only with pyran-or C.
parvum-activated PEC, but not with TGC-, or PP-elicited PEC, resident PEC, blood monocytes, neutrophils, spleen cells, bone marrow cells, or thymocytes. Although these results suggested that this AcM. 1 antibody was specific for activated macrophages, we further tested the reactivity of the AcM. 1 antibody by using purified macrophages (>95% nonspecific esterase-positive and phagocytic cells) from various PECs by plastic adherence. The results in Fig. 1 indicate that positive binding by the AcM. 1 monoclonal antibody was noted on activated macrophages induced by pyran or C. parvum, whereas TGC-, PP-, or mineral oil-elicited macrophages were found to be negative. In addition, resident macrophages were also shown to be negative (data not shown). Thus, the results indicated that this AcM. 1 monoclonal antibody was specific for activated macrophages.
Previous studies indicated that pyran and C. parvum are potent immunostimulants that render macrophages tumoricidal (18) . As shown in Fig. 2 , it is evident that tumoricidal capacity of macrophages was only associated with pyran-or C. parvumactivated cells but not with TGC-elicited macrophages. To directly demonstrate that tumoricidal macrophages bear the AcM. 1 antigen, we treated pyran-activated PEC with the AcM. 1 monoclonal antibody or anti-Thy-1 monoclonal antibody plus C and then tested for cytotoxicity against tumor cells. Fig. 3 shows that pretreatment of pyran-activated PEC with the AcM. 1 antibody plus C abolished ~80% cytotoxicity against tumor cells. However, the AcM. 1 antibody only or antibody plus heatinactivated (56°C for 30 min) C and anti-Thy-1 monoclonal antibody, as expected, did not affect cytotoxicity of macrophages. Thus, to our knowledge, this monoclonal antibody (AcM. 1) is the first unique marker of tumoricidal macrophages. A few years ago, Kaplan et al. (12) reported new cell surface antigens (AMthCSA) on activated macrophages, as determined by a heterologous antiserum adsorbed properly. The present study confirms the previous study and extends it by describing a monoclonal antibody (AcM. 1) that can discriminate activated macrophages from elicited or resident macrophages. However, relationship between AcM.1 and AMthCSA has not been established yet. Our preliminary experiment indicates that two polypeptides (67,000 and 44,000 mol wt) are identified as the AcM. 1 antigen (unpublished data). Thus, it is suggested that the AcM.1 antigen is different from Mac-l,2,3 (7, 8) , F4/80 (9, 10), and 2.6 (9, 10), detected by monoclonal antibodies and membrane-associated factor B (19) . However, further investigation is necessary to determine whether the AcM. 1 antigen is an acquired product (such as complement component) or an endogenous macrophage product.
In conclusion, all these data on the pattern of reactivity strongly indicate that the AcM. 1 antigen is a new cell surface marker for activated tumoricidal macrophages and should provide a useful probe to investigate the mechanisms of activation of macrophages. The relationship of this AcM. 1 antigen to the function of activated macrophages and to other macrophage antigens is now under investigation.
Summary
New activated macrophage-specific antigen (AcM. 1) detected by a monoclonal antibody has been described. The AcM. 1 antigen was only detectable on activated macrophages induced by pyran and Corynebactrium parvum but not on resident or thioglycollate medium (TGC), proteose-peptone, and mineral oil-elicited macrophages, and not on blood monocytes and neutrophils.
Activated macrophages induced by pyran and C. parvum, as expected, exhibited tumor cytotoxicity, whereas TGC-elicited macrophages did not show any cytotoxicity. Moreover, pretreatment of pyran-activated peritoneal exudate cells with AcM.1 antibody plus complement abolished ~80% cytotoxicity.
